Expedition Therapeutics' $165M raise Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 9 October, 2025

sponsored by Making complex cell therapies more cost-effective to scale. A must-read roadmap for global biotech leadership. Informed by an international workshop, the report outlines 11 priority actions to scale cell therapies from 100s to 10,000s of doses per year. Cutting through the complexity of process translation, discover how industry insiders are proposing to move the needle in constructive collaboration, automation, digitalisation, and business model innovation. Read the full report now

presented by The on­ly met­ric that mat­ters: en­roll­ment. How in­sid­ers on­ly pay for dosed pa­tients.

SPOTLIGHT Endpoints is building a Biopharma Sentiment Index: Take the industry survey In Focus David Reese bets his career on the 'hinge moment' for AI at Amgen

news Novo Nordisk to buy MASH player Akero for $4.7B upfront 'Running out of time': How LB Pharma landed the first big US biotech IPO since February Akero CEO is named chair of Expedition, which raised $165M for COPD drug from China Finnish researchers report success in mid-stage study of heart disease gene therapy Ferring to downsize by up to 500 staffers in move towards new ‘enterprise model’ Q&A: The scientists behind Baby KJ’s custom CRISPR drug are planning a trial to help more children

Oct 21 11:00am ET AI in life sciences: Reimagining teams, technology and partnerships for the future sponsored by Zaidyn by ZS

ESMO 2025 will deliver pivotal cancer trial data. Join Endpoints for strategic analysis of what matters most. Register now.

ENDPOINTS PHARMA UK drafts plans to pay up to 25% more for meds to appease drugmakers Lawyers scramble on how to advise clients on Trump’s 100% pharma tariff threat  CBER chief Prasad hires ARPA-H doctor as one of two new acting deputies ARPA-H awards several biotechs funding to make in vivo therapies Colorado drug board sets first state pricing limit for Amgen’s Enbrel in 2027

in case you missed it 1. Another biotech raises a megaround in race to get a new gout drug approved 2. Sanofi and radioligand partner Orano Med report mid-stage win in rare tumor 3. Eccogene files for Hong Kong IPO to back development of GLP-1 pipeline 4. News Briefing Shanghai biotech claims Phase 2 win in endometriosis; Karyopharm’s $100M 5.